Connect Biopharma (CNTB) Stock
Small biotech developing treatments for inflammatory diseases. Here's the price, business snapshot, and what's worth knowing about Connect Biopharma in May 2026.
Connect Biopharma Holdings (CNTB) is a development‑stage biopharmaceutical company focused on therapies for immune‑mediated inflammatory diseases. With a small market capitalisation (around $94m), the company’s valuation is driven primarily by clinical‑stage programmes, regulatory milestones and potential licensing or partnership deals rather than steady revenues. Investors should weigh upcoming trial readouts, the company’s cash runway and any financing risk, as small‑cap biotechs frequently face dilution and volatile share price moves. The competitive landscape includes larger pharmaceutical companies and other biotechs pursuing similar indications, which can influence licensing prospects. This is educational information only and not personalised advice; it may be of interest to investors with a high risk tolerance and a long‑term time horizon, while those seeking income or capital preservation may find it unsuitable. Always review company filings, clinical updates and liquidity metrics before considering an investment.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Connect Biopharma's stock with a target price of $47.75, indicating strong growth potential.
Financial Health
CONNECT BIOPHARMA HLDGS LTD has low revenue and cash flow, indicating financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CNTB
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory milestones can create sharp price moves; they may present opportunity but also significant downside if results are unfavourable.
Volatility & Financing Risk
Small‑cap biotechs often face dilution to fund operations and can experience wide swings in value. Check cash runway and recent financing history.
Partnerships Matter
Licensing or collaborations with larger firms can de‑risk programmes and unlock value, though such deals are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
